Pharma Business ITR - Section 35(2AB) R and D, Section 54(3) Inverted Duty Refund, and Section 37(1) Freebies Disallowance
📌 TL;DR - ITR for Pharma Businesses Services at a Glance
TL;DR: Pharma businesses file ITR-3 (proprietor), ITR-5 (LLP/firm), or ITR-6 (Pvt Ltd / listed). Tax audit applies above Rs 1 crore turnover (Rs 10 crore if 95 percent non-cash). R and D weighted deduction under Section 35(2AB) is now 100 percent (post 1 April 2020) capped at the DSIR-approved amount in Form 3CL. Freebies to doctors are fully disallowed under Apex Laboratories SC 2022. Audit-case ITR due 31 October 2026.
| Parameter | Detail |
|---|---|
| Governing Acts | Income-tax Act 1961 (Sec 35(2AB), 37(1) Expl 1+3, 44AB, 44AD, 139(1), 234A/B/C, 234F, 271B); CGST Act 2017 (Sec 54(3) inverted duty refund, Schedule I deemed supply); Drugs and Cosmetics Act 1940 (CDSCO licensing); ICDS-II Inventories |
| Applicable To | Pharma manufacturers, traders, chemists, OTC and FMCG pharma, API and formulation makers, exporters, SEZ units, R and D societies, HUF medical stores, Pvt Ltd and listed pharma companies |
| Section 35(2AB) R and D Deduction | 100 percent weighted deduction on in-house R and D expenditure (DSIR-approved facility) post 1 April 2020 - phased from 200% to 150% to 100% per Finance Act 2016. Capped at Form 3CL amount per Alembic Pharmaceuticals ITAT Ahmedabad March 2026 |
| Section 54(3) CGST Inverted Duty Refund | API at 18% input GST vs 5% output GST on finished medicines creates accumulated ITC. RFD-01 under Rule 89(5). 90 percent provisional refund effective 1 October 2025 per CGST Instruction 6/2025 |
| Section 37(1) Freebies Disallowance | 100 percent disallowance of doctor freebies, gifts, hospitality, gold coins, electronics, sponsored travel per Apex Laboratories vs DCIT SC 2022 + Section 37(1) Explanation 3 inserted by Finance Act 2022. Bona fide consultancy with deliverables still allowed |
| Tax Audit Threshold | Rs 1 crore turnover (Rs 10 crore if 95 percent receipts and payments non-cash). Form 3CA-3CD or 3CB-3CD due 30 September 2026. Section 271B penalty 0.5 percent of turnover or Rs 1.5 lakh whichever lower |
| Cost | Starting Rs 7,500 (Excl. GST and Govt. Charges) |
| Form / Portal | ITR-3 / ITR-5 / ITR-6 / ITR-7 on incometax.gov.in; Form 3CD audit; Form 3CK + 3CL DSIR R and D; Form 3CLA quantification; RFD-01 GST refund; Form 3CEB transfer pricing |
| Authority | CBDT (Income-tax Act); CBIC (GST); CDSCO (drug licensing under Drugs and Cosmetics Act 1940); DSIR (R and D approval); DGFT (foreign trade policy) |
All fees and charges listed are indicative only and do not constitute a binding offer. Final amounts may vary depending on the volume of work and the complexity involved.
Pharma businesses in India sit at the crossroads of three regulators: CBDT for income tax, CBIC for GST, and CDSCO for drug licensing under the Drugs and Cosmetics Act 1940. Filing an income tax return for a pharma manufacturer, trader, or chemist therefore is not a one-form exercise. ITR form selection, R and D weighted deduction under Section 35(2AB), GST inverted duty refund coordination under Section 54(3) of the CGST Act 2017, and the disallowance of doctor freebies under Section 37(1) Explanation 1 (Apex Laboratories Supreme Court ruling 2022 read with Explanation 3 inserted by Finance Act 2022) all interact in the same return.
API inputs commonly attract 18 percent GST while finished medicines attract 5 percent - creating accumulated ITC refundable under Section 54(3). Multi-state stock transfers between factory and depot are deemed supplies under Schedule I CGST Act with separate state GSTINs feeding into one PAN-level Schedule BP. Pharma exporters are largely excluded from RoDTEP and rely on duty drawback or Section 10AA SEZ benefits. ICDS-II governs inventory at lower of cost or NRV using FIFO or weighted average (LIFO not permitted). Patron Accounting handles the full pharma stack across Pune, Mumbai, Delhi, and Gurugram.
Content is reviewed quarterly for accuracy.